Global Neuroprotection Market - 2022-2029

Global Neuroprotection Market - 2022-2029

Market Overview

The global neuroprotection market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Neuroprotection is a kind of effect that can result in recovery, salvage and regeneration of the nervous system, structure, cells and function. There are various neurochemical modulators that damage the nervous system. It is the capability for therapy for neuronal cell death prevention by inhibiting any pathogenic cascade that results in cell dysfunction.

Market Dynamics

The major factors driving the global neuroprotection market are an increase in the number of neurodegenerative disorders globally, rising research and development expenditure and awareness among the population regarding these neuroprotection products. An increase in novel product launches contributes to the growth of the neuroprotection market.

The increasing investment in R&D, rising novel product launches, and drug discovery are expected to drive the market’s growth.

The rising adoption of these neuroprotection products for the prevention or treatment of various neurodegenerative disorders, such as Parkinson’s disease and multiple sclerosis, and the rising number of novel product launches drive the neuroprotection market. An increase in neurological diseases is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

Neuroprotection is used in various disorders such as stroke, trauma, Alzheimer's disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and stroke spinal muscular atrophy. The market for these applications is increasing worldwide due to the increasing number of cases. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market’s growth.

Various novel product launches, regulatory approvals and research studies contribute to the market’s growth. For instance, in July 5, 2022, Biogen Inc and TOKYO and CAMBRIDGE Eisai Co Ltd announced their Biologics License Application (BLA) for lecanemab, an anti-amyloid beta (Aβ) protofibril investigational antibody got accepted by the U.S. Food and Drug Administration. This antibody is used for mild cognitive impairment treatment that is caused due to Alzheimer’s disease and mild AD with amyloid pathology present in the brain.

The side effects associated with neuroprotection and the high cost are expected to hamper the market’s growth.

However, the minor population faces several side effects, as several products and medicines interact and release unwanted side effects. Several research studies suggest that dementia and brain function in some people can worsen due to vitamin E supplementation.

Various side effects are reported after using anti-excitotoxic agents, such as blurred vision, swelling of feet, confusion and hallucinations. The high cost of the treatment with neuroprotection is another factor limiting the neuroprotection market’s growth.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The neuroprotection market has experienced huge losses due to COVID, as various research and clinical trials got delayed and postponed due to the increasing cases of COVID. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in April 21, 2020, Novartis announced its Mayzent data in the medical journal, supplemental issue of neurology of the American Academy of Neurology of April. This data provides clinical evidence that Mayzent slows down the progression of physical disability and offers cognitive benefits in people having secondary progressive multiple sclerosis.

Segment Analysis

The free-radical trapping agent segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The free-radical trapping agent segment is the highest market holder in the global neuroprotection market. The global neuroprotection market is segmented based on product type: anti-inflammatory agents, free radical trapping agents, anti-excitotoxic agents, apoptosis inhibitors, iron chelators, neurotrophic factors, stimulants and gene therapy. The free-radical trapping agent segment is the largest market shareholder due to its better efficacy and results, increasing neurogenerative disorders and rising adoption of these neuroprotection products.

The free-radical trapping agents convert the disease-causing and damaging free radical cells into molecules that are more stable than earlier and easier to manage by the body. Antioxidants generally interact with these free radicals and reduce their impact. These can be found in plant-based food supplements. It has been observed that Vitamin E also possesses antioxidant properties in Alzheimer’s.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in June 24, 2021, Eli Lilly and Company announced that its Alzheimer’s disease antibody therapy, donanemab, had received breakthrough therapy designation by the United States Food and Drug Administration. This designation accelerates the development and review of drugs utilized for severe condition treatment if evidence of preliminary clinical trials suggests that it may show improvement over the marketed therapies with FDA approval.

Geographical Analysis

North America holds the largest market share in the global neuroprotection market.

North America dominates the global neuroprotection market, primarily due to its large population, excellent medical infrastructure, and the rising number of neurodegenerative disorders. According to Alzheimer’s Association report, in 2022, around 6.5 million Americans aged 65 will have Alzheimer’s. Around 1 out of 9 people 65 years or older have dementia; by 2050, this is expected to reach around 12.7 million. The increasing brain health issues, such as depression and dementia, boost the demand for neuroprotection products. Depression, stress, and anxiety are common mental illnesses among adolescents and millennials in the region.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market’s growth in this region. Advancement of applications of neuroprotection in Alzheimer's Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington’s Disease, Creutzfeldt-Jakob disease (CJD), Stroke, Spinal Muscular Atrophy and Others, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the neuroprotection market.

Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in July 26, 2022, Biogen Inc. announced its acceptance of a New Drug Application for an investigational drug, tofersen, utilized for superoxide dismutase 1 (SOD1) (ALS) amyotrophic lateral sclerosis. Priority review has been granted to the application, and further prescription drug user-free act action date have also been given.

Competitive Landscape

The neuroprotection market is moderately competitive with local and global companies’ presence. F. Hoffmann-La Roche AG, Eli Lilly and Company, Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Biogen, Astrocyte Pharmaceuticals, Inc., AbbVie Inc., Medtronic, Merck KGaA and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Oct 26, 2021, Teva Pharmaceuticals Industries Ltd. Announced its strategic collaboration with MODAG GmbH on worldwide exclusive licensing and development of anle 138b, a lead compound of MODAG and sery433, a related compound. Anle 138b is a small molecule candidate targeting disease modification for several neurological disorders, including multiple system atrophy.

F. Hoffmann-La Roche AG.

Overview: Roche is a healthcare company that provides in-vitro diagnostics and supplies solutions that are innovative as well as transformative in various crucial disease areas. It works in two divisions: Pharmaceuticals and diagnostics. It was established in 1896 and is headquartered in Basel, Switzerland.

Product Portfolio:

Ocrelizumab: Ocrevus is a monoclonal humanized antibody that targets CD20-positive B cells with a major role in multiple sclerosis. This therapy is the first approved for primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. It is in the final stage and will be available in the market in 2023.

Key Developments: In February 15, 2022, Roche announced its agreement with Aquinnah Pharmaceuticals for amyotrophic lateral sclerosis and neurodegenerative diseases by advancing brain penetrant oral small molecules development.

The global neuroprotection market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.